Navigation Links
Pharmacyclics Announces It Received Nasdaq Notification
Date:4/21/2008

SUNNYVALE, Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it received a Nasdaq staff deficiency letter on April 17, 2008 indicating that, for the last 30 consecutive days, the bid price for Pharmacyclics' common stock has closed below the minimum bid price of requirement of $1.00 per share for continued inclusion on The Nasdaq Global Market under Marketplace Rule 4450(a)(5). In accordance with Marketplace Rule 4450(e)(2), Pharmacyclics has 180 calendar days, or until October 14, 2008, to regain compliance. If Pharmacyclics does not regain compliance by October 14, 2008, Nasdaq will provide written notification that Pharmacyclics' common stock will be delisted, after which Pharmacyclics may appeal the staff determination to the Nasdaq Listing Qualifications Panel if it so chooses. There can be no assurance that Pharmacyclics will satisfy Nasdaq's conditions for continued listing, that any potential appeal or hearing for a stay of delisting will be successful or that Pharmacyclics' common stock will remain listed on The Nasdaq Global Market.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and immune mediated diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
4. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
5. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
8. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
9. US Oncology Announces Resignation of Chief Financial Officer
10. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
11. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... Can economic incentives such as gift cards, ... the public to increase their donations of blood? , ... Business School Assistant Professor Mario Macis says the ... body of recent research that supports their argument, the ... of Science that the World Health Organization and national ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
(Date:5/23/2013)... -- Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a ... and therapeutics, announced today that StemCyte has become an ... car driven by James Jakes . ... 2013 season.   StemCyte, Inc. and Rahal Letterman ... umbilical cord blood banking and its educational initiative ,Stars ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... Increase In Total Revenue To $5.6 Million; 34% Increase ... -- International Isotopes Inc. (OTC Bulletin Board: INIS) ... 31, 2008. Total Revenue . ... in 2007, which represents an increase of $911,885 or ...
... Fla., March 27 Catalyst Pharmaceutical Partners, Inc. ... that acquires, in-licenses, develops and commercializes prescription drugs ... financial results for the fourth quarter and year ... 2008," said Patrick J. McEnany, Chief Executive Officer ...
... sensitivity of Magnetic Resonance techniques including those used in ... scientists at the University of York. , Ultimately, the ... space shuttle, is expected to allow doctors to learn ... scan at lower cost while increasing the range of ...
Cached Biology Technology:International Isotopes Inc. Announces Year End Financial Results 2International Isotopes Inc. Announces Year End Financial Results 3International Isotopes Inc. Announces Year End Financial Results 4Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 2Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 3Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 4Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 5Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 6Transforming medical diagnosis with new scanning technology 2
(Date:5/23/2013)... world are billions of animal and plant specimens from ... all stacked, stored and preserved in jars and collection ... critical to understanding how the Earth,s biodiversity is changing ... if only the information were easily accessible. , A ... of a team from the University of Colorado Boulder, ...
(Date:5/22/2013)... Trial (NLST) investigators also conclude that the 20 ... computed tomography (LDCT) versus chest X-ray (CXR) screening ... achievable at experienced screening centers in the United ... share with their patients about the benefits and ... publication in the New England Journal of ...
(Date:5/22/2013)... streamlined approach to genetic engineering drastically reduces the ... into bacteria, the workhorses of biotechnology, scientists are ... Biology , the method paves the way for ... development, environmental cleanup and other activities. , Keith ... a piece of the genetic material DNA into ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... , , , , ... AUDIO: Dr Andrew Marshall, from the Environment Department at the University of York, ... Click here for more information. , , , ... , , , , , , ...
... Carlos Mara Romeo Casabona is Director of the Interuniversity Professorship ... the University of the Basque Country. The Professorship is largely ... as researchers in the fields of molecular biology, medicine and ... and the Humane Genome at the Universities of Deusto and ...
... CINCINNATI -- Children exposed prenatally to tobacco smoke and ... ADHD, according to research done at Cincinnati Children,s Hospital Medical ... of ADHD cases in children between the ages of 8 ... environmental exposures. This could translate into up to 800,000 children ...
Cached Biology News:New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Research and legislation should go hand in hand, as much as possible 2Exposure to lead, tobacco smoke raises risk of ADHD 2
... The MSD Security ... integrated GC/MS software application ... processing, quantification, library searching ... the aspects of data ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Soil Nematode microRNA Microarray ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: